Keith Peden

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s
    Keith Peden
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 370:63-76. 2008
  2. pmc Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc
    Li Sheng-Fowler
    Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Int J Biol Sci 6:151-62. 2010
  3. doi request reprint A quantitative PCR assay for SV40 neutralization adaptable for high-throughput applications
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    J Virol Methods 162:236-44. 2009
  4. pmc Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 5:e14416. 2010
  5. doi request reprint Identification of a neutralization epitope in the VP1 capsid protein of SV40
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products CBER, FDA Bethesda, MD 20892, USA
    Virology 381:116-22. 2008
  6. pmc Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e56023. 2013
  7. pmc Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells
    Romelda L Omeir
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and DrugAdministration, National Institutes of Health, Bethesda, Maryland, USA
    Comp Med 61:243-50. 2011
  8. ncbi request reprint Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage
    Haruhiko Murata
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 370:343-51. 2008
  9. doi request reprint Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: Evaluation of methods for DNA inactivation
    Li Sheng-Fowler
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Research and Evaluation, Food and Drug Administration, Bethesda, MD 20892, USA
    Biologicals 37:259-69. 2009
  10. doi request reprint Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    Vaccine 29:3155-61. 2011

Collaborators

  • Haruhiko Murata
  • Yong Zhu
  • James L Cook
  • Meropi Athanasiou
  • Majid Laassri
  • Philip D Minor
  • Andrew M Lewis
  • Belete Teferedegne
  • Li Sheng-Fowler
  • Brian Orrison
  • Achintya Pal
  • Jan C Varada
  • Romelda L Omeir
  • John M Coffin
  • Fang Cai
  • Stephen H Hughes
  • Manu Manohar
  • Li Sheng
  • Jinho Shin
  • Lev Sirota
  • Emmanuel Desmezieres
  • JUDY BEELER
  • R Lynne Crim
  • Thembi Mdluli
  • Susette Audet
  • Lauren R Brinster
  • Joel J Beren
  • Philip J Snoy
  • Gideon S Foseh
  • Mariam Quinones
  • Haiqing Fu
  • Gideon Foseh
  • Don G Blair
  • Donald G Blair
  • James Robertson
  • David Wood
  • Thomas Maudru
  • Nidhi Gupta
  • Yong He
  • Russell Vassell
  • Zhongning Yang
  • Carol D Weiss
  • Paul Wingfield

Detail Information

Publications17

  1. ncbi request reprint Recovery of strains of the polyomavirus SV40 from rhesus monkey kidney cells dating from the 1950s to the early 1960s
    Keith Peden
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Virology 370:63-76. 2008
    ..These results, and those of others, suggest that a limited number of SV40 strains might exist in rhesus macaques in the United States, and thus determining the origin of the SV40 sequences detected in human tumors might be difficult...
  2. pmc Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc
    Li Sheng-Fowler
    Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Int J Biol Sci 6:151-62. 2010
    ..Based on these data, the dual-expression plasmid pMSV-T24-H-ras/MSV-c-myc will be used as the positive control to develop a sensitive and quantitative animal assay that can be used to assess the oncogenic activity of DNA...
  3. doi request reprint A quantitative PCR assay for SV40 neutralization adaptable for high-throughput applications
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    J Virol Methods 162:236-44. 2009
    ..A similar high-throughput approach might be feasible for related polyomaviruses (e.g., BKV and JCV) as well as for other families of viruses...
  4. pmc Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 5:e14416. 2010
    ..These results may prove to be relevant to the biology of neoplastic development. In addition, one or more of these miRNAs could be biomarkers for the expression of a tumorigenic phenotype...
  5. doi request reprint Identification of a neutralization epitope in the VP1 capsid protein of SV40
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products CBER, FDA Bethesda, MD 20892, USA
    Virology 381:116-22. 2008
    ..Structural information regarding the neutralization epitope should be useful for clarifying the extent of cross-reactivity exhibited by the humoral immune response towards related primate polyomaviruses (e.g., SV40, BKV, and JCV)...
  6. pmc Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR
    Belete Teferedegne
    Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e56023. 2013
    ..Finally, our qRT-PCR-based approach may be broadly applicable to the development of neutralization assays for a wide variety of viruses...
  7. pmc Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells
    Romelda L Omeir
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and DrugAdministration, National Institutes of Health, Bethesda, Maryland, USA
    Comp Med 61:243-50. 2011
    ..Such data also are useful when considering MDCK cells as a reagent for vaccine manufacture...
  8. ncbi request reprint Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage
    Haruhiko Murata
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 370:343-51. 2008
    ..This VP1 mutation was identified as a genetic determinant influencing a number of phenotypes associated with SV40-LP(KT) such as plaque morphology, intracellular vacuole formation, and ganglioside receptor usage...
  9. doi request reprint Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: Evaluation of methods for DNA inactivation
    Li Sheng-Fowler
    Laboratory of Retrovirus Research, Division of Viral Products, Center for Biologics Research and Evaluation, Food and Drug Administration, Bethesda, MD 20892, USA
    Biologicals 37:259-69. 2009
    ..Thus, the potential risk associated with DNA can be substantially reduced by degradation or by chemical inactivation...
  10. doi request reprint Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds
    Haruhiko Murata
    Laboratory of DNA Viruses, Division of Viral Products, CBER, FDA, Bethesda, MD 20892, USA
    Vaccine 29:3155-61. 2011
    ....
  11. doi request reprint Oncogenicity of DNA in vivo: tumor induction with expression plasmids for activated H-ras and c-myc
    Li Sheng
    Division of Viral Products, OVRR, CBER, FDA, Building 29A, Room 3D08, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Biologicals 36:184-97. 2008
    ..Such information provides a possible way of evaluating and estimating the theoretical oncogenic risk posed by residual cell-substrate DNA in vaccines...
  12. ncbi request reprint Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses
    Achintya Pal
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Virol Methods 135:32-42. 2006
    ..5 and 1 copy of the JCV genome. We suggest that the virus-specific primer/probe sets in this study be considered sufficiently characterized to initiate the quantification of polyomavirus DNA in biological samples...
  13. pmc A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment
    Jan C Varada
    Laboratory of DNA Viruses, Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Virol J 10:195. 2013
    ..Its lack of use may not be surprising considering that sample nucleic acid extraction and purification can be expensive, labor-intensive, and rate-limiting...
  14. doi request reprint Issues associated with residual cell-substrate DNA in viral vaccines
    Li Sheng-Fowler
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drugs Administration, Bethesda, MD 20892, USA
    Biologicals 37:190-5. 2009
    ....
  15. ncbi request reprint Assessing the tumorigenic phenotype of VERO cells in adult and newborn nude mice
    Manu Manohar
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Room 1B10, Building 29A, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Biologicals 36:65-72. 2008
    ..Higher tumor incidences and shorter tumor latencies suggest that newborn nude mice may be more sensitive than adults in detecting the expression of a tumorigenic phenotype by some VERO cell lines...
  16. pmc Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120
    Emmanuel Desmezieres
    U S Food and Drug Administration, Center for Biologics Evaluation and Research, HFM 466, Bldg 29, Room 532, 8800 Rockville Pike, Bethesda, MD 20892 4555, USA
    J Virol 79:4774-81. 2005
    ..The results are discussed in the context of current models of Env-mediated membrane fusion...
  17. ncbi request reprint WHO informal consultation on the application of molecular methods to assure the quality, safety and efficacy of vaccines, Geneva, Switzerland, 7-8 April 2005
    Jinho Shin
    World Health Organization, Department of Immunizations, Vaccines and Biologicals, Avenue Appia, CH 1211 Geneva, Switzerland
    Biologicals 35:63-71. 2007
    ....